Li Jiang is a partner in our corporate transactions practice
Li's practice focuses on international capital markets and corporate transactions. She has extensive experience advising investment banks and corporates on Rule 144A and Regulation S securities offerings, including listings on the Hong Kong Stock Exchange, share placings and secondary offerings throughout Asia.
Li received her Juris Doctor degree, magna cum laude, from Washington University School of Law. She received her Master's degree in Economics from the University of Pennsylvania and Bachelor's degree in Economics & Finance from the University of Hong Kong.
Li is a native speaker of Mandarin and speaks fluent English and Cantonese.
Li is qualified in the state of New York and is admitted as a solicitor in Hong Kong.
Latest thinking
Carousel: clicking the "Previous" or "Next" button changes the content between the buttons.
-
Legal development
Are you ready? Upcoming changes to the Hong Kong Corporate Governance Code
05 Jun 2025
Discover more -
Legal development
Seamless Transition: Hong Kong's New Company Re-domiciliation Regime
30 May 2025
Discover more -
Legal development
Hong Kong Stock Exchange – new regime for treasury shares
19 Apr 2024
Discover more -
Legal development
Hong Kong Stock Exchange puts climate-related disclosures in the spotlight
24 Apr 2023
Discover more -
Legal development
New path for technology companies to list in Hong Kong
27 Mar 2023
Discover more -
Legal development
Consultation on the Hong Kong Listing Rules relating to PRC issuers
02 Mar 2023
Discover more -
Legal development
Hong Kong Stock Exchange - 2022 Analysis of ESG Practice Disclosure
02 Dec 2022
Discover more -
Legal development
Revised rules for share schemes of HK listed companies
11 Aug 2022
Discover more -
Legal development
Enhancements to the corporate governance code
16 Dec 2021
Discover more
Latest news, deals and awards
Carousel: clicking the "Previous" or "Next" button changes the content between the buttons.
-
News Ashurst advises on China's pharmaceutical company HXPharma’s HK$993.6 million Hong Kong IPO
20 Oct 2025
Discover more -
News Ashurst advises on Butong Group’s HK$781.84 million Hong Kong IPO
23 Sep 2025
Discover more -
News Ashurst advises on China's biotech firm Cloudbreak Pharma’s Hong Kong IPO
03 Jul 2025
Discover more -
News Ashurst advises UBS on HK$400 million placing of new H shares by Shandong Boan Biotechnology
12 Jun 2025
Discover more -
News Ashurst advises on China's new generation sweetener manufacturer Newtrend Group's Hong Kong IPO
10 Jun 2025
Discover more -
News Ashurst represents Shanghai Voicecomm Information Technology in its Hong Kong IPO
18 Jul 2024
Discover more